Advances in chemotherapy for patients with extremity soft tissue sarcoma.
Doxorubicin-based chemotherapy does not appear to offer a survival benefit to patients who have high-risk primary extremity soft tissue sarcomas, whereas ifosfamide-based chemotherapy does. This benefit is likely histology- and size-specific. Until a less toxic targeted systemic therapy is developed, treatment with ifosfamide should be strongly considered in patients who have high-risk primary extremity soft tissue sarcomas.
Eilber
Fritz C
FC
University of California, Los Angeles, UCLA Medical Center, 90095-1782, USA. fceilber@mednet.ucla.edu
Tap
William D
WD
Nelson
Scott D
SD
Eckardt
Jeffery J
JJ
Eilber
Frederick R
FR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005121:Extremities; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods*; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D016019:Survival Analysis
D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide